JPM vs LIEN
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
JPM exhibits a concerning Piotroski F-Score of 2/9, indicating weak short-term fundamental health, and currently trades at a significant premium to both its Graham Number ($239.11) and Intrinsic Value ($140.07). While the company maintains a strong ROE of 16.13% and dominant market positioning, negative YoY earnings growth (-3.60%) and bearish insider activity from the CEO and CFO signal internal caution. The stock's current price of $313.68 suggests the market is pricing in a growth premium that is not currently supported by the deterministic health or value metrics.
LIEN presents a classic 'value trap' profile, characterized by a very weak Piotroski F-Score of 2/9 indicating deteriorating fundamental health despite trading at a massive discount to its Graham Number ($20.9) and Intrinsic Value ($17.67). While the valuation metrics (P/E 6.32, P/B 0.69) are highly attractive, the technical trend is completely bearish (0/100) and the dividend payout ratio of 93.15% leaves almost no margin for error. The company shows steady revenue growth, but the lack of earnings momentum and poor health score suggest the market is pricing in significant underlying risk.
Compare Another Pair
Related Comparisons
JPM vs LIEN: Head-to-Head Comparison
This page compares JPMorgan Chase & Co. (JPM) and Chicago Atlantic BDC, Inc. (LIEN) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.